A5033923828- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Cervical Cancer and HPV Research
- Intraperitoneal and Appendiceal Malignancies
- Endometriosis Research and Treatment
- Cancer Genomics and Diagnostics
- Uterine Myomas and Treatments
- Renal cell carcinoma treatment
- Colorectal and Anal Carcinomas
- Sarcoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Chemotherapy-related skin toxicity
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Management of metastatic bone disease
- Nonmelanoma Skin Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Retinoids in leukemia and cellular processes
Women & Infants Hospital of Rhode Island
2016-2025
Brown University
2016-2025
Providence College
2015-2024
Medical College of Wisconsin
2023
Dana-Farber Cancer Institute
2007-2023
Cancer Research UK
2023
AstraZeneca (Italy)
2023
Clinica Universidad de Navarra
2023
The University of Texas MD Anderson Cancer Center
2020-2023
AstraZeneca (Brazil)
2023
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but as maintenance therapy is uncertain.
Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance initial treatment patients high-grade serous ovarian carcinoma. In an international, phase 3, placebo-controlled trial, we assessed efficacy veliparib added to first-line induction carboplatin and paclitaxel continued monotherapy previously untreated stage III or IV Patients were randomly assigned a 1:1:1 ratio...
Germline mutations in BRCA1 and BRCA2 are relatively common women with ovarian, fallopian tube, peritoneal carcinoma (OC) causing a greatly increased lifetime risk of these cancers, but the frequency relevance inherited other genes is less well characterized.To determine importance germline cancer-associated OC.A study population 1915 woman OC available DNA were identified from University Washington (UW) gynecologic tissue bank (n = 570) Gynecologic Oncology Group (GOG) phase III clinical...
Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.
A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency drug delivery) plus carboplatin every 3 weeks or the addition bevacizumab to and administered has shown efficacy ovarian cancer. We proposed determine whether would prolong progression-free survival as compared with among patients receiving those not bevacizumab.
The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate high-risk early-stage endometrial carcinoma.
In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients newly diagnosed advanced ovarian cancer and BRCA1 and/or BRCA2 (BRCA) mutation. We report overall (OS) after 7-year follow-up, clinically relevant time point longest follow-up for any first-line setting.This double-blind phase III trial randomly assigned BRCA mutation clinical response to...
Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated phase 3 investigation.
It is often difficult to distinguish a benign pelvic mass from malignancy and tools help referring physician are needed. The purpose of this study was validate the Risk Ovarian Malignancy Algorithm in women presenting with mass.This prospective, multicenter, blinded clinical trial that included who presented gynecologist, family practitioner, an internist, or general surgeon adnexal mass. Serum HE4 CA 125 were determined preoperatively. A score calculated classified patients into high-risk...
Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in treatment endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP.GOG0209 was phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage IV, recurrent cancers; performance status 0-2; adequate renal, hepatic, marrow function. Prior radiotherapy and/or hormonal therapy permitted,...
To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.
Purpose The clinicopathologic significance of mismatch repair (MMR) defects in endometrioid endometrial cancer (EEC) has not been definitively established. We undertook tumor typing to classify MMR determine if status is prognostic or predictive. Methods Primary EECs from NRG/GOG0210 patients were assessed for microsatellite instability (MSI), MLH1 methylation, and protein expression. Each was assigned one four classes: normal, epigenetic defect, probable mutation (MMR defect attributable...
Purpose The best screening practice for Lynch syndrome (LS) in endometrial cancer (EC) remains unknown. We sought to determine whether tumor microsatellite instability (MSI) typing along with immunohistochemistry (IHC) and MLH1 methylation analysis can help identify women LS. Patients Methods ECs from GOG210 patients were assessed MSI, methylation, mismatch repair (MMR) protein expression. Each was classified as having normal MMR, defective MMR associated or probable mutation (ie, but no...
This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to ifosfamide (PI) for treating uterine carcinosarcoma (UCS).Adults with chemotherapy-naïve UCS or ovarian (OCS) were randomly assigned PC PI 3-week cycles 6-10 cycles. With 264 events in patients UCS, power an overall survival (OS) hybrid noninferiority design was 80% a hazard ratio (HR) of 1.2 against 13% greater death rate on type I error 5% one-tailed test.The study...
To evaluate the prognostic factors in locally advanced cervical cancer limited to pelvis and develop nomograms for 2-year progression-free survival (PFS), 5-year overall (OS), pelvic recurrence. We retrospectively reviewed 2,042 patients with carcinoma enrolled onto Gynecologic Oncology Group clinical trials of concurrent cisplatin-based chemotherapy radiotherapy. Nomograms PFS, five-year OS, recurrence were created as visualizations Cox proportional hazards regression models. The models...
Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO high-risk noncarriers, optimal surgical age, anatomic origin clinically occult detected at surgery. To address these topics, we analyzed treatment arm results Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention Early Detection Study.This analysis included...
Purpose This prospective, randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute Canada Clinical Trials was designed to test effectiveness safety adding hypoxic cell sensitizer tirapazamine (TPZ) standard cisplatin (CIS) chemoradiotherapy in locally advanced cervix cancer. Patients Methods with cancer were randomly assigned CIS versus CIS/TPZ chemoradiotherapy. Primary end point progression-free survival (PFS). Secondary points included overall...